Celularity Inc.
Investor Relations
About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (MLASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Latest Press Releases
Events & Presentations
AACR 2024 Abstract #5232 – Placental Circulating T Cells Expressing CD16 in Combination with Trastuzumab Demonstrate Robust Anti-tumor Antibody-dependent Cellular Cytotoxicity (ADCC) Against Gastric Cancer
April 10, 2024, at 3:13 pm ET
Celularity Investor Presentation
Last Updated June, 2022
Jefferies Cell and Genetic Medicine Summit
September 30, 2022, at 11:00 am ET
Celularity at Morgan Stanley 20th Annual Global Healthcare Conference
September 14, 2022, at 12:20 pm ET
Celularity at H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022, at 1:30 pm ET
Celularity at Oppenheimer 32nd Annual Healthcare Conference
March 17, 2022 at 11:20 AM
Celularity at Oppenheimer 32nd Annual Healthcare Conference
March 17, 2022 at 11:20 AM
Celularity Inc. to Host Investor and Analyst Research & Development Day
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells